{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:46:23Z","timestamp":1794667583507,"version":"4.9.1"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,10,19]]},"DOI":"10.1038\/s41416-025-03100-7","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:00:41Z","timestamp":1751630441000},"page":"919-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3173-1011","authenticated-orcid":false,"given":"Jincai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"3100_CR1","volume":"3","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Prim. 2017;3:17036.","journal-title":"Nat Rev Dis Prim"},{"key":"3100_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"3100_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","volume":"7","author":"ZN Lei","year":"2022","unstructured":"Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7:358.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3100_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine. 2022;47:101404.","journal-title":"EClinicalMedicine"},{"key":"3100_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"3100_CR7","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0820-4","volume":"21","author":"FM Johnston","year":"2019","unstructured":"Johnston FM, Beckman M. Updates on management of gastric cancer. Curr Oncol Rep. 2019;21:67.","journal-title":"Curr Oncol Rep"},{"key":"3100_CR8","doi-asserted-by":"crossref","unstructured":"Rao X, Zhang C, Luo H, Zhang J, Zhuang Z, Liang Z, et al. Targeting gastric cancer stem cells to enhance treatment response. Cells. 2022;11:2828.","DOI":"10.3390\/cells11182828"},{"key":"3100_CR9","volume":"173","author":"J Liu","year":"2024","unstructured":"Liu J, Yuan Q, Guo H, Guan H, Hong Z, Shang D. Deciphering drug resistance in gastric cancer: potential mechanisms and future perspectives. Biomed Pharmacother. 2024;173:116310.","journal-title":"Biomed Pharmacother"},{"key":"3100_CR10","doi-asserted-by":"crossref","unstructured":"Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. cancer control. 2022;29:10732748221099227.","DOI":"10.1177\/10732748221099227"},{"key":"3100_CR11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12672-024-01374-6","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liao Y, Huang L, Luo Z. Exploring copper metabolism-induced cell death in gastric cancer: a single-cell RNA sequencing study and prognostic model development. Discov Oncol. 2024;15:482.","journal-title":"Discov Oncol"},{"key":"3100_CR12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR13","doi-asserted-by":"crossref","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283.","DOI":"10.3390\/ijms20061283"},{"key":"3100_CR14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med. 2022;3:538\u201364.","journal-title":"Med"},{"key":"3100_CR15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26:1878\u201387.","journal-title":"Nat Med"},{"key":"3100_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10555-024-10228-0","volume":"44","author":"TJ Kearl","year":"2024","unstructured":"Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. Cancer Metastasis Rev. 2024;44:12.","journal-title":"Cancer Metastasis Rev"},{"key":"3100_CR17","doi-asserted-by":"crossref","unstructured":"Maciocia NC, Wade BG, Maciocia PM. CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Adv. 2024;9:913\u201323.","DOI":"10.1182\/bloodadvances.2023012263"},{"key":"3100_CR18","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"3100_CR19","doi-asserted-by":"crossref","unstructured":"Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, et al. CAR-T-cell therapy in multiple myeloma: B-Cell Maturation Antigen (BCMA) and beyond. Vaccines. 2023;11:1721.","DOI":"10.3390\/vaccines11111721"},{"key":"3100_CR20","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","volume":"19","author":"R Awasthi","year":"2023","unstructured":"Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah(R) (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. Hum Vaccin Immunother. 2023;19:2210046.","journal-title":"Hum Vaccin Immunother"},{"key":"3100_CR21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"3100_CR22","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang DH, Zhao HB. CAR T-Cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22:67.","journal-title":"Mol Cancer"},{"key":"3100_CR23","first-page":"20","volume":"122","author":"DS Aschenbrenner","year":"2022","unstructured":"Aschenbrenner DS. New approval for drug treating large B-cell lymphoma. Am J Nurs. 2022;122:20\u20131.","journal-title":"Am J Nurs"},{"key":"3100_CR24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"3100_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","volume":"553","author":"J Yang","year":"2023","unstructured":"Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Lett. 2023;553:215949.","journal-title":"Cancer Lett"},{"key":"3100_CR26","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"3100_CR27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398.","journal-title":"Nat Med"},{"key":"3100_CR28","first-page":"2182","volume":"327","author":"HD Larkin","year":"2022","unstructured":"Larkin HD. CAR T-cell therapy shows early promise for gastrointestinal cancer. JAMA. 2022;327:2182.","journal-title":"JAMA"},{"key":"3100_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121459","volume":"318","author":"M Entezam","year":"2023","unstructured":"Entezam M, Sanaei MJ, Mirzaei Y, Mer AH, Abdollahpour-Alitappeh M, Azadegan-Dehkordi F, et al. Current progress and challenges of immunotherapy in gastric cancer: a focus on CAR-T cells therapeutic approach. Life Sci. 2023;318:121459.","journal-title":"Life Sci"},{"key":"3100_CR30","doi-asserted-by":"crossref","unstructured":"Rojas-Quintero J, Diaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D, et al. Car T cells in solid tumors: overcoming obstacles. Int J Mol Sci. 2024;25:4170.","DOI":"10.3390\/ijms25084170"},{"key":"3100_CR31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","volume":"9","author":"Y Song","year":"2018","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9:867\u201378.","journal-title":"Protein Cell"},{"key":"3100_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","volume":"12","author":"J Lv","year":"2019","unstructured":"Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12:18.","journal-title":"J Hematol Oncol"},{"key":"3100_CR33","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang C, Wang J, Che S, Zhao H. CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon. 2023;9:e21776.","journal-title":"Heliyon"},{"key":"3100_CR34","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3100_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","volume":"14","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow DJ, Walunas TL, Bluestone JA. CD28\/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233\u201358.","journal-title":"Annu Rev Immunol"},{"key":"3100_CR36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1073\/pnas.96.1.185","volume":"96","author":"PA Bretscher","year":"1999","unstructured":"Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA. 1999;96:185\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3100_CR37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18:413\u201320.","journal-title":"Mol Ther"},{"key":"3100_CR38","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31:3146\u201362.","journal-title":"Mol Ther"},{"key":"3100_CR39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","volume":"168","author":"P Yuti","year":"2023","unstructured":"Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, et al. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother. 2023;168:115691.","journal-title":"Biomed Pharmacother"},{"key":"3100_CR40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566\u201381.","journal-title":"Nat Rev Cancer"},{"key":"3100_CR41","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22.","journal-title":"Biomark Res"},{"key":"3100_CR42","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.","journal-title":"Front Immunol"},{"key":"3100_CR43","volume":"126","author":"J Zhou","year":"2024","unstructured":"Zhou J, Shi F, Luo X, Lei B, Shi Z, Huang C, et al. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR. Int Immunopharmacol. 2024;126:111239.","journal-title":"Int Immunopharmacol"},{"key":"3100_CR44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","volume":"17","author":"R Tan","year":"2024","unstructured":"Tan R, Li R, Dai MY, Liu M, Zhao J. Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China\u2019s responses to address secondary cancer risks of CAR-T therapy. J Hematol Oncol. 2024;17:90.","journal-title":"J Hematol Oncol"},{"key":"3100_CR45","doi-asserted-by":"crossref","unstructured":"Feola S, Chiaro J, Martins B, Cerullo V. Uncovering the tumor antigen landscape: what to know about the discovery process. Cancers. 2020;12:1660.","DOI":"10.3390\/cancers12061660"},{"key":"3100_CR46","doi-asserted-by":"crossref","unstructured":"Zang PD, Angeles A, Pal SK. CD70: an emerging anticancer target in renal cell carcinoma and beyond. Annu Rev Med. 2024;76:257\u201366.","DOI":"10.1146\/annurev-med-070623-045906"},{"key":"3100_CR47","doi-asserted-by":"crossref","unstructured":"Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T cell therapy overview of targets in gastric cancer. J Clin Med. 2020;9:1894.","DOI":"10.3390\/jcm9061894"},{"key":"3100_CR48","volume":"7","author":"M Yang","year":"2024","unstructured":"Yang M, Lin W, Huang J, Mannucci A, Luo H. Novel immunotherapeutic approaches in gastric cancer. Precis Clin Med. 2024;7:pbae020.","journal-title":"Precis Clin Med"},{"key":"3100_CR49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","volume":"16","author":"MC Mathias-Machado","year":"2024","unstructured":"Mathias-Machado MC, de Jesus VHF, Jacome A, Donadio MD, Aruquipa MPS, Fogacci J, et al. Claudin 18.2 as a new biomarker in gastric cancer-what should we know? Cancers. 2024;16:679.","journal-title":"Cancers"},{"key":"3100_CR50","volume":"611","author":"A Tojjari","year":"2024","unstructured":"Tojjari A, Idrissi YA, Saeed A. Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Lett. 2024;611:217362.","journal-title":"Cancer Lett"},{"key":"3100_CR51","volume":"47","author":"SI Lyu","year":"2024","unstructured":"Lyu SI, Fretter C, Simon AG, Spielmann SM, Damanakis AI, Zhao Y, et al. Extent and clinical significance of the therapy-relevant tight junction protein claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Transl Oncol. 2024;47:102044.","journal-title":"Transl Oncol"},{"key":"3100_CR52","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38.","journal-title":"Biomark Res"},{"key":"3100_CR53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409\u201318.","journal-title":"J Natl Cancer Inst"},{"key":"3100_CR54","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334.","journal-title":"Nat Med"},{"key":"3100_CR55","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","volume":"25","author":"E Rubin","year":"2024","unstructured":"Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, et al. Molecular targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) genes across various cancers. Int J Mol Sci. 2024;25:1064.","journal-title":"Int J Mol Sci"},{"key":"3100_CR56","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.","journal-title":"Mol Biol Int"},{"key":"3100_CR57","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.2147\/JIR.S368138","volume":"15","author":"J Sun","year":"2022","unstructured":"Sun J, Li X, Chen P, Gao Y. From anti-HER-2 to anti-HER-2-CAR-T cells: an evolutionary immunotherapy approach for gastric cancer. J Inflamm Res. 2022;15:4061\u201385.","journal-title":"J Inflamm Res"},{"key":"3100_CR58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3892\/ijo.2024.5624","volume":"64","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Zhao H, Chen ZS, Shi X, Chen XB. HER2(+) advanced gastric cancer: current state and opportunities (Review). Int J Oncol. 2024;64:36.","journal-title":"Int J Oncol"},{"key":"3100_CR59","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469\u201387.","journal-title":"Oncogene"},{"key":"3100_CR60","doi-asserted-by":"crossref","unstructured":"Alrhmoun S, Sennikov S. The role of tumor-associated antigen HER2\/neu in tumor development and the different approaches for using it in treatment: many choices and future directions. Cancers. 2022;14:6173.","DOI":"10.3390\/cancers14246173"},{"key":"3100_CR61","volume":"14","author":"S Cen","year":"2024","unstructured":"Cen S, Yuan M, Sun Q, Hou G, Ying J, Xu Q, et al. Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study. Sci Rep. 2024;14:25030.","journal-title":"Sci Rep"},{"key":"3100_CR62","volume":"5","author":"Y Ding","year":"2024","unstructured":"Ding Y, Yuan Y, Weng S. KEYNOTE-811: potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer. MedComm. 2024;5:e545.","journal-title":"MedComm"},{"key":"3100_CR63","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","volume":"10","author":"R Hassan","year":"2004","unstructured":"Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937\u201342.","journal-title":"Clin Cancer Res"},{"key":"3100_CR64","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1245\/s10434-021-10507-y","volume":"28","author":"K Nagata","year":"2021","unstructured":"Nagata K, Shinto E, Shiraishi T, Yamadera M, Kajiwara Y, Mochizuki S, et al. Mesothelin expression is correlated with chemoresistance in stage IV colorectal cancer. Ann Surg Oncol. 2021;28:8579\u201386.","journal-title":"Ann Surg Oncol"},{"key":"3100_CR65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","volume":"442","author":"MC Chang","year":"2012","unstructured":"Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao TL, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways. Biochem J. 2012;442:293\u2013302.","journal-title":"Biochem J"},{"key":"3100_CR66","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","volume":"32","author":"U Bharadwaj","year":"2011","unstructured":"Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011;32:1013\u201324.","journal-title":"Carcinogenesis"},{"key":"3100_CR67","volume":"16","author":"T Xu","year":"2024","unstructured":"Xu T, Tian T, Wang C, Chen X, Zuo X, Zhou H, et al. Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study. Genome Med. 2024;16:133.","journal-title":"Genome Med"},{"key":"3100_CR68","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3390\/biomedicines12112584","volume":"12","author":"M Bak","year":"2024","unstructured":"Bak M, Wojciech M, Pielech A, Holka S, Zawadzki M, Murawa D. The advancement stage of gastric cancer and the levels of CEA and Ca19-9 in serum and peritoneal lavage. Biomedicines. 2024;12:2584.","journal-title":"Biomedicines"},{"key":"3100_CR69","doi-asserted-by":"crossref","unstructured":"Wu G, Wang D, Xiong F, Wang Q, Liu W, Chen J, et al. The emerging roles of CEACAM6 in human cancer (Review). Int J Oncol. 2024;64:27.","DOI":"10.3892\/ijo.2024.5615"},{"key":"3100_CR70","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.120716","volume":"214","author":"W Xiang","year":"2020","unstructured":"Xiang W, Lv Q, Shi H, Xie B, Gao L. Aptamer-based biosensor for detecting carcinoembryonic antigen. Talanta. 2020;214:120716.","journal-title":"Talanta"},{"key":"3100_CR71","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1002\/cam4.2361","volume":"8","author":"X Chi","year":"2019","unstructured":"Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, et al. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Med. 2019;8:4753\u201365.","journal-title":"Cancer Med"},{"key":"3100_CR72","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25:1248\u201358.","journal-title":"Mol Ther"},{"key":"3100_CR73","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","volume":"22","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021;22:6567.","journal-title":"Int J Mol Sci"},{"key":"3100_CR74","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bulcan.2022.08.001","volume":"109","author":"L Qing","year":"2022","unstructured":"Qing L, Li Q, Dong Z. MUC1: an emerging target in cancer treatment and diagnosis. Bull Cancer. 2022;109:1202\u201316.","journal-title":"Bull Cancer"},{"key":"3100_CR75","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn9857","volume":"10","author":"P Erler","year":"2024","unstructured":"Erler P, Kurcon T, Cho H, Skinner J, Dixon C, Grudman S, et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Sci Adv. 2024;10:eadn9857.","journal-title":"Sci Adv"},{"key":"3100_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85747-9","volume":"11","author":"K Supimon","year":"2021","unstructured":"Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep. 2021;11:6276.","journal-title":"Sci Rep"},{"key":"3100_CR77","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901\u20139.","journal-title":"J Immunol"},{"key":"3100_CR78","doi-asserted-by":"crossref","unstructured":"Gaber A, Lenarcic B, Pavsic M. Current view on EpCAM structural biology. Cells. 2020;9:1361.","DOI":"10.3390\/cells9061361"},{"key":"3100_CR79","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-6-253","volume":"6","author":"F Kroepil","year":"2013","unstructured":"Kroepil F, Dulian A, Vallbohmer D, Geddert H, Krieg A, Vay C, et al. High EpCAM expression is linked to proliferation and Lauren classification in gastric cancer. BMC Res Notes. 2013;6:253.","journal-title":"BMC Res Notes"},{"key":"3100_CR80","volume":"13","author":"P Ding","year":"2023","unstructured":"Ding P, Chen P, Ouyang J, Li Q, Li S. Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis. Front Oncol. 2023;13:1242231.","journal-title":"Front Oncol"},{"key":"3100_CR81","doi-asserted-by":"crossref","unstructured":"Yang Y, Louie R, Puc J, Vedvyas Y, Alcaina Y, Min IM, et al. Chimeric antigen receptor T cell therapy targeting epithelial cell adhesion molecule in gastric cancer: mechanisms of tumor resistance. Cancers. 2023;15:5552.","DOI":"10.3390\/cancers15235552"},{"key":"3100_CR82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12876-024-03286-9","volume":"24","author":"S Zeng","year":"2024","unstructured":"Zeng S, Jin N, Yu B, Ren Q, Yan Z, Fu S. Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer. BMC Gastroenterol. 2024;24:249.","journal-title":"BMC Gastroenterol"},{"key":"3100_CR83","volume":"9","author":"D Qin","year":"2020","unstructured":"Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology. 2020;9:1806009.","journal-title":"Oncoimmunology"},{"key":"3100_CR84","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9:eadg9721.","journal-title":"Sci Adv"},{"key":"3100_CR85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","volume":"33","author":"FZ Nawaz","year":"2022","unstructured":"Nawaz FZ, Kipreos ET. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022;33:159\u201374.","journal-title":"Trends Endocrinol Metab"},{"key":"3100_CR86","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2637-y","volume":"16","author":"S Notaro","year":"2016","unstructured":"Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rossler J, et al. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers. BMC Cancer. 2016;16:589.","journal-title":"BMC Cancer"},{"key":"3100_CR87","doi-asserted-by":"crossref","first-page":"e0198347","DOI":"10.1371\/journal.pone.0198347","volume":"13","author":"M Kim","year":"2018","unstructured":"Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE. 2018;13:e0198347.","journal-title":"PLoS ONE"},{"key":"3100_CR88","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-157","volume":"10","author":"LE Kandalaft","year":"2012","unstructured":"Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med. 2012;10:157.","journal-title":"J Transl Med"},{"key":"3100_CR89","volume":"5","author":"J Obajdin","year":"2024","unstructured":"Obajdin J, Larcombe-Young D, Glover M, Kausar F, Hull CM, Flaherty KR, et al. Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Rep Med. 2024;5:101827.","journal-title":"Cell Rep Med"},{"key":"3100_CR90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00262-024-03795-2","volume":"73","author":"A Herault","year":"2024","unstructured":"Herault A, Mak J, de la Cruz-Chuh J, Dillon MA, Ellerman D, Go M, et al. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity. Cancer Immunol Immunother. 2024;73:209.","journal-title":"Cancer Immunol Immunother"},{"key":"3100_CR91","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9:2064\u201378.","journal-title":"Am J Cancer Res"},{"key":"3100_CR92","doi-asserted-by":"crossref","unstructured":"Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K. NKG2D Natural killer cell receptor-A short description and potential clinical applications. Cells. 2021;10:1420.","DOI":"10.3390\/cells10061420"},{"key":"3100_CR93","first-page":"747","volume":"15","author":"R Kamei","year":"2018","unstructured":"Kamei R, Yoshimura K, Yoshino S, Inoue M, Asao T, Fuse M, et al. Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy. Oncol Lett. 2018;15:747\u201354.","journal-title":"Oncol Lett"},{"key":"3100_CR94","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00280-018-3670-0","volume":"82","author":"K Tao","year":"2018","unstructured":"Tao K, He M, Tao F, Xu G, Ye M, Zheng Y, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharm. 2018;82:815\u201327.","journal-title":"Cancer Chemother Pharm"},{"key":"3100_CR95","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab018","volume":"1","author":"S Curio","year":"2021","unstructured":"Curio S, Jonsson G, Marinovic S. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 2021;1:ltab018.","journal-title":"Immunother Adv"},{"key":"3100_CR96","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7:100\u201312.","journal-title":"Cancer Immunol Res"},{"key":"3100_CR97","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"3100_CR98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14.","journal-title":"Exp Hematol Oncol"},{"key":"3100_CR99","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"3100_CR100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","volume":"17","author":"H Huang","year":"2024","unstructured":"Huang H, Yu L, Weng H, Zhang W, Wang Z, Wang L, et al. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. J Hematol Oncol. 2024;17:120.","journal-title":"J Hematol Oncol"},{"key":"3100_CR101","doi-asserted-by":"crossref","unstructured":"Ma K, Wang L, Li W, Tang T, Ma B, Zhang L, et al. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends Cancer. 2024;11:117\u201334.","DOI":"10.1016\/j.trecan.2024.11.011"},{"key":"3100_CR102","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23:175.","journal-title":"Mol Cancer"},{"key":"3100_CR103","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Macedo NA, Brussolo NM, Haddad F, et al. Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022;13:947648.","journal-title":"Front Immunol"},{"key":"3100_CR104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17:105.","journal-title":"J Hematol Oncol"},{"key":"3100_CR105","doi-asserted-by":"crossref","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2024;43:506\u201315.","DOI":"10.1038\/s41587-024-02446-2"},{"key":"3100_CR106","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li Z, Sun X, Men W, Xu Y. Cellular components of tumor microenvironment: understanding their role in lymphatic metastasis of tumors. Front Pharmacol. 2024;15:1463538.","journal-title":"Front Pharmacol"},{"key":"3100_CR107","volume":"14","author":"J Luo","year":"2024","unstructured":"Luo J, Zhang X. Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol. 2024;14:1399544.","journal-title":"Front Oncol"},{"key":"3100_CR108","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"3100_CR109","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"key":"3100_CR110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","volume":"5","author":"HJ Jackson","year":"2015","unstructured":"Jackson HJ, Brentjens RJ. Overcoming antigen escape with CAR T-cell therapy. Cancer Discov. 2015;5:1238\u201340.","journal-title":"Cancer Discov"},{"key":"3100_CR111","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023;186:1432\u201347.e17.","journal-title":"Cell"},{"key":"3100_CR112","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.","journal-title":"Curr Opin Biotechnol"},{"key":"3100_CR113","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188701","volume":"1877","author":"P Akbari","year":"2022","unstructured":"Akbari P, Katsarou A, Daghighian R, van Mil L, Huijbers EJM, Griffioen AW, et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer. 2022;1877:188701.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3100_CR114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"key":"3100_CR115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9:176.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR116","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai Z, Feng B, McClory SE, de Oliveira BC, Diorio C, Gregoire C, et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature. 2024;634:702\u201311.","journal-title":"Nature"},{"key":"3100_CR117","volume":"136","author":"J Hu","year":"2024","unstructured":"Hu J, Liu X. Generation of CAR-T(SCM): CAR-T with super clutch. Int Immunopharmacol. 2024;136:112379.","journal-title":"Int Immunopharmacol"},{"key":"3100_CR118","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10:86.","journal-title":"Biomark Res"},{"key":"3100_CR119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"key":"3100_CR120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"3100_CR121","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Muller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34\u201348.","journal-title":"Ann Oncol"},{"key":"3100_CR122","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.","journal-title":"J Immunother Cancer"},{"key":"3100_CR123","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40:367.","journal-title":"J Exp Clin Cancer Res"},{"key":"3100_CR124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR125","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024;23:56.","journal-title":"Mol Cancer"},{"key":"3100_CR126","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-10443-5","volume":"24","author":"MC Cavallo","year":"2024","unstructured":"Cavallo MC, Cavazza M, Bonifazi F, Casadei B, Cutini I, Tonietti B, et al. Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study. BMC Health Serv Res. 2024;24:121.","journal-title":"BMC Health Serv Res"},{"key":"3100_CR127","doi-asserted-by":"crossref","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.","DOI":"10.1084\/jem.20230903"},{"key":"3100_CR128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40487-023-00228-5","volume":"11","author":"S Jagannath","year":"2023","unstructured":"Jagannath S, Joseph N, Crivera C, Kharat A, Jackson CC, Valluri S, et al. Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma. Oncol Ther. 2023;11:263\u201375.","journal-title":"Oncol Ther"},{"key":"3100_CR129","first-page":"121","volume":"7","author":"MA Rehman","year":"2024","unstructured":"Rehman MA, Arshad H. A discount on the cost of cancer: India\u2019s homegrown CAR-T cell therapy. Blood Cell Ther. 2024;7:121\u20133.","journal-title":"Blood Cell Ther"},{"key":"3100_CR130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379.","journal-title":"Cancer Cell"},{"key":"3100_CR131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21147\/j.issn.1000-9604.2023.03.03","volume":"35","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang Y. Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors. Chin J Cancer Res. 2023;35:239\u201344.","journal-title":"Chin J Cancer Res"},{"key":"3100_CR132","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81.","journal-title":"Stem Cell Res Ther"},{"key":"3100_CR133","doi-asserted-by":"crossref","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13:eabe7378.","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"3100_CR134","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25:479\u201389.","journal-title":"Curr Oncol Rep"},{"key":"3100_CR135","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183\u201397.","journal-title":"EMBO Mol Med"},{"key":"3100_CR136","volume":"201","author":"KD S S","year":"2024","unstructured":"SS KD, Joga R, Srivastava S, Nagpal K, Dhamija I, Grover P, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. Eur J Pharm Biopharm. 2024;201:114361.","journal-title":"Eur J Pharm Biopharm"},{"key":"3100_CR137","volume":"22","author":"M Yue","year":"2023","unstructured":"Yue M, Hu S, Sun H, Tuo B, Jia B, Chen C, et al. Extracellular vesicles remodel tumor environment for cancer immunotherapy. Mol Cancer. 2023;22:203.","journal-title":"Mol Cancer"},{"key":"3100_CR138","doi-asserted-by":"crossref","unstructured":"Liu Y, Liang J, Zhang Y, Guo Q. Drug resistance and tumor immune microenvironment: an overview of current understandings (Review). Int J Oncol. 2024;65:96.","DOI":"10.3892\/ijo.2024.5684"},{"key":"3100_CR139","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359.","journal-title":"Cancer Discov"},{"key":"3100_CR140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJN.S441135","volume":"19","author":"C Peng","year":"2024","unstructured":"Peng C, Xu Y, Wu J, Wu D, Zhou L, Xia X. TME-related biomimetic strategies against cancer. Int J Nanomed. 2024;19:109\u201335.","journal-title":"Int J Nanomed"},{"key":"3100_CR141","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.ymthe.2017.04.026","volume":"25","author":"S Quader","year":"2017","unstructured":"Quader S, Kataoka K. Nanomaterial-enabled cancer therapy. Mol Ther. 2017;25:1501\u201313.","journal-title":"Mol Ther"},{"key":"3100_CR142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"3100_CR143","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41:421\u201333.","journal-title":"Cancer Cell"},{"key":"3100_CR144","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7150\/thno.51777","volume":"11","author":"D Chen","year":"2021","unstructured":"Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11:1016\u201330.","journal-title":"Theranostics"},{"key":"3100_CR145","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","volume":"19","author":"YX Zhang","year":"2019","unstructured":"Zhang YX, Zhao YY, Shen J, Sun X, Liu Y, Liu H, et al. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates Anti-PD-1 therapy. Nano Lett. 2019;19:2774\u201383.","journal-title":"Nano Lett"},{"key":"3100_CR146","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41401-020-0423-5","volume":"41","author":"FL Qi","year":"2020","unstructured":"Qi FL, Wang MF, Li BZ, Lu ZF, Nie GJ, Li SP. Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharm Sin. 2020;41:895\u2013901.","journal-title":"Acta Pharm Sin"},{"key":"3100_CR147","volume":"14","author":"SK Daniel","year":"2024","unstructured":"Daniel SK, Sullivan KM, Dickerson LK, van den Bijgaart RJE, Utria AF, Labadie KP, et al. Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade. Sci Rep. 2024;14:5109.","journal-title":"Sci Rep"},{"key":"3100_CR148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16.","journal-title":"J Hematol Oncol"},{"key":"3100_CR149","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5483\/BMBRep.2024-0031","volume":"57","author":"SA Lim","year":"2024","unstructured":"Lim SA. Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy. BMB Rep. 2024;57:388\u201399.","journal-title":"BMB Rep"},{"key":"3100_CR150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.it.2024.05.006","volume":"45","author":"Y Agarwala","year":"2024","unstructured":"Agarwala Y, Brauns TA, Sluder AE, Poznansky MC, Gemechu Y. Targeting metabolic pathways to counter cancer immunotherapy resistance. Trends Immunol. 2024;45:486\u201394.","journal-title":"Trends Immunol"},{"key":"3100_CR151","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.","journal-title":"Mol Cancer"},{"key":"3100_CR152","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189164","volume":"1879","author":"X Peng","year":"2024","unstructured":"Peng X, He Z, Yuan D, Liu Z, Rong P. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2024;1879:189164.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3100_CR153","doi-asserted-by":"crossref","unstructured":"Rahman MA, Yadab MK, Ali MM. Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy. Cells. 2024;13:1924.","DOI":"10.3390\/cells13221924"},{"key":"3100_CR154","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25:249\u201358.","journal-title":"Mol Ther"},{"key":"3100_CR155","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR156","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539\u201360.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR157","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402:142\u201358.","journal-title":"Lancet"},{"key":"3100_CR158","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93:290\u20136.","journal-title":"Immunol Cell Biol"},{"key":"3100_CR159","doi-asserted-by":"crossref","unstructured":"Jeong S, Park E, Kim HD, Sung E, Kim H, Jeon J, et al. Novel anti-4-1BBxPD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. 2021;9:e002428.","DOI":"10.1136\/jitc-2021-002428"},{"key":"3100_CR160","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30:2537\u201353.","journal-title":"Mol Ther"},{"key":"3100_CR161","volume":"10","author":"SW Huang","year":"2023","unstructured":"Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, et al. BiTE-Secreting CAR-gammadeltaT as a dual targeting strategy for the treatment of solid tumors. Adv Sci. 2023;10:e2206856.","journal-title":"Adv Sci"},{"key":"3100_CR162","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, et al. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72:3773\u201386.","journal-title":"Cancer Immunol Immunother"},{"key":"3100_CR163","volume":"31","author":"G Cao","year":"2022","unstructured":"Cao G, Zhang G, Liu M, Liu J, Wang Q, Zhu L, et al. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay. Biochem Biophys Rep. 2022;31:101324.","journal-title":"Biochem Biophys Rep"},{"key":"3100_CR164","volume":"23","author":"J Wei","year":"2024","unstructured":"Wei J, Li W, Zhang P, Guo F, Liu M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024;23:279.","journal-title":"Mol Cancer"},{"key":"3100_CR165","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21:451\u201372.","journal-title":"Cancer Biol Med"},{"key":"3100_CR166","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9:543\u201353.","journal-title":"Trends Cancer"},{"key":"3100_CR167","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3100_CR168","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mi.2024.137","volume":"4","author":"V Shah","year":"2024","unstructured":"Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S. Immune checkpoint inhibitors in metastatic melanoma therapy (Review). Med Int. 2024;4:13.","journal-title":"Med Int"},{"key":"3100_CR169","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"3100_CR170","doi-asserted-by":"crossref","unstructured":"Lao Y, Shen D, Zhang W, He R, Jiang M. Immune checkpoint inhibitors in cancer therapy-how to overcome drug resistance? Cancers. 2022;14:3575.","DOI":"10.3390\/cancers14153575"},{"key":"3100_CR171","volume":"14","author":"Y Lv","year":"2024","unstructured":"Lv Y, Luo X, Xie Z, Qiu J, Yang J, Deng Y, et al. Prospects and challenges of CAR-T cell therapy combined with ICIs. Front Oncol. 2024;14:1368732.","journal-title":"Front Oncol"},{"key":"3100_CR172","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122387","volume":"338","author":"S Najafi","year":"2024","unstructured":"Najafi S, Mortezaee K. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: a focus on anti PD-1\/PD-L1 antibodies. Life Sci. 2024;338:122387.","journal-title":"Life Sci"},{"key":"3100_CR173","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"3100_CR174","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124211","volume":"659","author":"S Parit","year":"2024","unstructured":"Parit S, Manchare A, Gholap AD, Mundhe P, Hatvate N, Rojekar S, et al. Antibody-drug conjugates: a promising breakthrough in cancer therapy. Int J Pharm. 2024;659:124211.","journal-title":"Int J Pharm"},{"key":"3100_CR176","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1016\/j.apsb.2024.06.007","volume":"14","author":"Y Lei","year":"2024","unstructured":"Lei Y, Shen Y, Chen F, He R, Zhang Z, Zhou Y, et al. Multiepitope recognition technology promotes the in-depth analysis of antibody\u2012drug conjugates. Acta Pharm Sin B. 2024;14:4962\u201376.","journal-title":"Acta Pharm Sin B"},{"key":"3100_CR177","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22:365.","journal-title":"Cancer Cell Int"},{"key":"3100_CR178","first-page":"3","volume":"11","author":"MR Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11:3\u201323.","journal-title":"Avicenna J Med Biotechnol"},{"key":"3100_CR179","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, et al. CAR-armored-cell therapy in solid tumor treatment. J Transl Med. 2024;22:1076.","journal-title":"J Transl Med"},{"key":"3100_CR180","first-page":"95","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins ER, D\u2019Souza RR, Klampatsa A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics. 2021;15:95\u2013105.","journal-title":"Biologics"},{"key":"3100_CR181","doi-asserted-by":"crossref","unstructured":"Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K, et al. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med. 2021;13:eaba7308.","DOI":"10.1126\/scitranslmed.aba7308"},{"key":"3100_CR182","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629:201\u201310.","journal-title":"Nature"},{"key":"3100_CR183","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"3100_CR184","doi-asserted-by":"crossref","first-page":"279","DOI":"10.52601\/bpr.2023.230020","volume":"9","author":"Y Cui","year":"2023","unstructured":"Cui Y, Luo M, Gu C, He Y, Yao Y, Li P. CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy. Biophys Rep. 2023;9:279\u201397.","journal-title":"Biophys Rep"},{"key":"3100_CR185","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3:100543.","journal-title":"Cell Rep Med"},{"key":"3100_CR186","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","volume":"124","author":"M Imamura","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124:1081\u20138.","journal-title":"Blood"},{"key":"3100_CR187","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692982","volume":"9","author":"DE Mascarelli","year":"2021","unstructured":"Mascarelli DE, Rosa RSM, Toscaro JM, Semionatto IF, Ruas LP, Fogagnolo CT, et al. Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T-cell receptors. Front Cell Dev Biol. 2021;9:692982.","journal-title":"Front Cell Dev Biol"},{"key":"3100_CR188","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.omto.2020.06.018","volume":"18","author":"P Nguyen","year":"2020","unstructured":"Nguyen P, Okeke E, Clay M, Haydar D, Justice J, O\u2019Reilly C, et al. Route of 41BB\/41BBL costimulation determines effector function of B7-H3-CAR.CD28zeta T cells. Mol Ther Oncolytics. 2020;18:202\u201314.","journal-title":"Mol Ther Oncolytics"},{"key":"3100_CR189","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie YQ, Huang X, et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer. Nature. 2024;634:712\u201320.","journal-title":"Nature"},{"key":"3100_CR190","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42:1693\u2013704.","journal-title":"Nat Biotechnol"},{"key":"3100_CR191","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21:78.","journal-title":"Mol Cancer"},{"key":"3100_CR192","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Riviere I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13:829\u201343.","journal-title":"Cancer Discov"},{"key":"3100_CR193","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348.","journal-title":"Nature"},{"key":"3100_CR194","volume":"95","author":"Z Huang","year":"2023","unstructured":"Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, et al. Application of oncolytic virus in tumor therapy. J Med Virol. 2023;95:e28729.","journal-title":"J Med Virol"},{"key":"3100_CR195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163.","journal-title":"Front Immunol"},{"key":"3100_CR196","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14:eabn2231.","journal-title":"Sci Transl Med"},{"key":"3100_CR197","doi-asserted-by":"crossref","unstructured":"Stilpeanu RI, Secara BS, Cretu-Stancu M, Bucur O. Oncolytic viruses as reliable adjuvants in CAR-T cell therapy for solid tumors. Int J Mol Sci. 2024;25:11127.","DOI":"10.3390\/ijms252011127"},{"key":"3100_CR198","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","volume":"9","author":"S Guedan","year":"2018","unstructured":"Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol. 2018;9:2460.","journal-title":"Front Immunol"},{"key":"3100_CR199","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR200","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11899-019-00537-5","volume":"14","author":"Z Walsh","year":"2019","unstructured":"Walsh Z, Ross S, Fry TJ. Multi-specific CAR targeting to prevent antigen escape. Curr Hematol Malig Rep. 2019;14:451\u20139.","journal-title":"Curr Hematol Malig Rep."},{"key":"3100_CR201","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","volume":"10","author":"JJ van der Schans","year":"2020","unstructured":"van der Schans JJ, van de Donk N, Mutis T. Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment. Front Oncol. 2020;10:1362.","journal-title":"Front Oncol"},{"key":"3100_CR202","doi-asserted-by":"crossref","unstructured":"Xie B, Li Z, Zhou J, Wang W. Current status and perspectives of dual-targeting chimeric antigen receptor T-Cell therapy for the treatment of hematological malignancies. Cancers. 2022;14:3230.","DOI":"10.3390\/cancers14133230"},{"key":"3100_CR203","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1111\/bph.16505","volume":"181","author":"S Ruixin","year":"2024","unstructured":"Ruixin S, Yifan L, Yansha S, Min Z, Yiwei D, Xiaoli H, et al. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. Br J Pharm. 2024;181:4628\u201346.","journal-title":"Br J Pharm"},{"key":"3100_CR204","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","volume":"11","author":"E Zhang","year":"2018","unstructured":"Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11:102.","journal-title":"J Hematol Oncol"},{"key":"3100_CR205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14:161.","journal-title":"J Hematol Oncol"},{"key":"3100_CR206","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuca G, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2:904\u201318.","journal-title":"Nat Cancer"},{"key":"3100_CR207","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJMe2304744","volume":"389","author":"DL Longo","year":"2023","unstructured":"Longo DL. Engineering CAR T cells for off-the-shelf use. N Engl J Med. 2023;389:953\u20137.","journal-title":"N Engl J Med"},{"key":"3100_CR208","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1491282","volume":"12","author":"M Alidadi","year":"2024","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biol. 2024;12:1491282.","journal-title":"Front Cell Dev Biol"},{"key":"3100_CR209","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Rev Clin Oncol. 2025;22:10\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"3100_CR210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"3100_CR211","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-024-01550-9","volume":"17","author":"Y Kang","year":"2024","unstructured":"Kang Y, Li C, Mei H. Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting. J Hematol Oncol. 2024;17:29.","journal-title":"J Hematol Oncol"},{"key":"3100_CR212","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396:1885\u201394.","journal-title":"Lancet"},{"key":"3100_CR213","volume":"10","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hu Y, Mei H. Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies. Adv Sci. 2023;10:e2303215.","journal-title":"Adv Sci"},{"key":"3100_CR214","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629:211\u20138.","journal-title":"Nature"},{"key":"3100_CR215","doi-asserted-by":"crossref","unstructured":"Kumar J, Kumar R, Kumar Singh A, Tsakem EL, Kathania M, Riese MJ, et al. Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 2021;9:e001688.","DOI":"10.1136\/jitc-2020-001688"},{"key":"3100_CR216","volume":"9","author":"SM Collins","year":"2023","unstructured":"Collins SM, Alexander KA, Lundh S, Dimitri AJ, Zhang Z, Good CR, et al. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Sci Adv. 2023;9:eadh2605.","journal-title":"Sci Adv"},{"key":"3100_CR217","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40164-023-00450-x","volume":"12","author":"M Liu","year":"2023","unstructured":"Liu M, Zhang L, Zhong M, Long Y, Yang W, Liu T, et al. CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro. Exp Hematol Oncol. 2023;12:88.","journal-title":"Exp Hematol Oncol"},{"key":"3100_CR218","doi-asserted-by":"crossref","unstructured":"Walsh ZH, Shah P, Kothapalli N, Shah SB, Nikolenyi G, Brodtman DZ, et al. Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens. Nat Biotechnol. 2024;43:384\u201395.","DOI":"10.1038\/s41587-024-02235-x"},{"key":"3100_CR219","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao G, Zhang Y, Xu CF, Wang J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull. 2024;69:354\u201366.","journal-title":"Sci Bull"},{"key":"3100_CR220","doi-asserted-by":"crossref","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023;11:e006292.","DOI":"10.1136\/jitc-2022-006292"},{"key":"3100_CR221","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10555-024-10185-8","volume":"43","author":"R Hou","year":"2024","unstructured":"Hou R, Zhang X, Wang X, Zhao X, Li S, Guan Z, et al. In vivo manufacture and manipulation of CAR-T cells for better druggability. Cancer Metastasis Rev. 2024;43:1075\u201393.","journal-title":"Cancer Metastasis Rev"},{"key":"3100_CR222","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"key":"3100_CR223","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol Ther. 2020;28:1783\u201394.","journal-title":"Mol Ther"},{"key":"3100_CR224","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","volume":"8","author":"Z Xia","year":"2024","unstructured":"Xia Z, Jin Q, Long Z, He Y, Liu F, Sun C, et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat Biomed Eng. 2024;8:1634\u201350.","journal-title":"Nat Biomed Eng"},{"key":"3100_CR225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu S, Chen J, Wu T, Li L, Wang G, Wu H, et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 2024;34:386\u20138.","journal-title":"Cell Res"},{"key":"3100_CR226","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, et al. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol. 2023;14:1273507.","journal-title":"Front Immunol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03100-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:04:11Z","timestamp":1759154651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03100-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":226,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10,19]]}},"alternative-id":["3100"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03100-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}